Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma


A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma




This is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing, single doses of Toca 511, a Retroviral Replicating Vector (RRV), administered transcranially to subjects with recurrent high grade glioma (rHGG) who have undergone surgery, radiation therapy and chemotherapy with temozolomide. Approximately 3-4 weeks following injection of the RRV, treatment with oral 5-FC will commence and will be repeated monthly for up to 6 cycles.

Study Status: Recruiting

Cathy Brewer, RN 216-444-7937

Condition Intervention Phase
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Biological: Toca 511
Drug: 5-FC
Phase 1/Phase 2

Verified by Tocagen Inc. November, 2012

Sponsored by: Tocagen Inc.
Information provided by: Tocagen Inc. identifier: NCT01156584

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site